From January 1, 2024 to March 31, 2024, the company has repurchased 156,200 shares, representing 1.33% for CAD 1.31 million. With this, the company has completed the repurchase of 176,300 shares, representing 1.5% for CAD 1.48 million under the buyback announced on December 13, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.5 CAD | +4.90% | +10.41% | +13.88% |
05-17 | Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2023. | CI |
05-17 | BioSyent Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.88% | 90.27M | |
+51.63% | 796B | |
+41.51% | 628B | |
-5.10% | 358B | |
+19.90% | 331B | |
+9.95% | 301B | |
+17.66% | 244B | |
+3.39% | 228B | |
+10.75% | 214B | |
+6.99% | 165B |
- Stock Market
- Equities
- RX Stock
- News BioSyent Inc.
- Tranche Update on BioSyent Inc. (TSXV: RX)'s Equity Buyback Plan announced on December 13, 2023.